In the international CONVINCE trial, presented today (15 May 2024) at the European Stroke Organisation Conference (ESOC) 2024, anti-inflammatory treatment with long-term colchicine did not reduce rates of recurrent stroke and cardiovascular events in patients with non-cardioembolic stroke in the primary intention-to-treat analysis.
Jim Wilson’s GemmaBio raises $34M to commercialize gene therapies for rare diseases
GemmaBio, a company founded by gene therapy pioneer Jim Wilson, has raised $34 million in seed funding to try and resuscitate the floundering gene therapy